The first loss in half a year

In the evening of July 11, Laimei Pharmaceutical Co., Ltd released the semi annual performance forecast of 2014 It is estimated that from January to June, the company will lose 22 million yuan to 27 million yuan, compared with the profit of 37.27 million yuan in the same period last year     For the first half year report card of loss after listing, Laimei pharmaceutical explained four reasons: first, the new base of tea garden preparation project was put into production for a short time, the production capacity has not been fully normalized, coupled with the large investment in fixed assets of the project, resulting in a large change in the production structure, as well as a large increase in the depreciation of fixed assets and the operating costs of the production base; second, the subsidiary Kang Yuan The new base of Yiyang Pharmaceutical Co., Ltd and Chengdu Jinxing Pharmaceutical Co., Ltd have not been officially put into production, resulting in the increase of relevant expenses during the period; the third is the expansion of the company's financing scale, resulting in a substantial increase of financial expenses on a year-on-year basis; the fourth is the sharp decrease of government subsidies on a year-on-year basis According to Mo Xiaobin, sales director of New Drug Department of Laimei pharmaceutical, after successfully passing the new GMP certification, the first 300000 laimeishu capsules have officially entered the dealer network since last week and will be sold in major hospitals across the country At present, the company has covered 60% of the top three hospitals in China, and the goal for the whole year is 80% According to the company's strategic planning and product market capacity calculation, it is expected that "laimeishu" will achieve a sales volume of about 1 billion yuan in about three years According to the Research Report of huitianfu fund, the listing of "laimeishu" has broken AstraZeneca's monopoly on the domestic market, provided more clinical options for hundreds of millions of patients nationwide, and will rapidly expand the existing market scale of esomeprazole In the future, based on the good market foundation, high recognition and academic status of this variety, "laimeishu" will co-exist with imported varieties to jointly develop the market Mo Xiaobin also told China Securities Com that the company managed and controlled dealers through a refined model, so as to sign sales tasks and agreements with the corresponding dealers in each hospital, so as to ensure that the sales volume of lemesu in the shortest time Up to now, more than 20 major provinces and municipalities have completed the dealer network coverage, and the remaining regions are in the process of negotiation with customers "Although a new round of bidding has not been carried out in China, as an exclusive heavy-duty product, lemesu has significant advantages in the supplementary bidding." Mo Xiaobin said that the product can be sold in public hospitals in corresponding regions after the successful completion of bid supplement / bidding; next, it can also be sold in national digestive specialized hospitals and private hospitals "Utilins" is the immunomodulator Mycobacterium phlei f.u.36 injection, which is mainly used in the treatment of respiratory system diseases, malignant tumors, skin diseases and many other diseases related to immune function It has been proved by modern medicine and immunology research that it has a rare "CpG structure" in human cells, which can trigger the active immune process of human body, adjust the immune function of human body to the best state, and produce a lasting immune adjustment ability, without long-term dependence on drug stimulation In 1995, Jinxing Pharmaceutical Co., Ltd imported from Germany and produced and sold exclusively in China Its curative effect has been widely recognized by the society and entered the national medical insurance catalogue According to the person in charge of Jinxing Pharmaceutical Co., Ltd., after Laimei Pharmaceutical Co., Ltd became the owner of the company in an all-round way, it changed the original production mode of "imported original solution and domestic sub packaging" through negotiation with the German side, and adopted the new mode of "strain import and domestic cultivation production" At the same time of upgrading the new GMP, it moved the original production line of Germany to China as it is, and implemented the same production process and standard as the original factory Accurate In addition, Jinxing Pharmaceutical Co., Ltd has expanded its annual production capacity of less than 4 million to 50 million / year at one stroke, completely solving the problem of insufficient production capacity, and avoiding the quality problems caused by long-distance transportation and long-term storage of raw liquid At the beginning of this year, more than 100 agents from more than 10 provinces and municipalities directly under the central government, such as Shanghai, Jiangsu, Chongqing, Sichuan, Liaoning, Anhui, Guangdong, Hunan, Yunnan and Jiangxi, have signed agency agreements since the company started the investment promotion work of Utilins, and other provinces have intention to cooperate with each other As of May, more than 300 hospitals have been targeted, including more than 100 hospitals above the top three, and they are still increasing "According to the current schedule, Utilins is expected to go on sale at the end of July According to the number of target hospitals, the number of patients treated by the health and Family Planning Commission and the overall situation of the immune regulation market, the company expects the annual sales of Utilins to exceed 1 billion yuan in five years, "said Mo Xiaobin According to the analysis of researchers in the pharmaceutical industry of Everbright financial holding, the annual sales volume of "Utilins" and "laimeishu" are expected to reach more than 1 billion yuan, which will become a strong catalyst for the rapid growth of the future performance of laimeishu pharmaceutical industry However, its impact on the company's performance in the second half of this year mainly depends on the progress of relevant bidding